![How I manage patients with follicular lymphoma - Casulo - 2019 - British Journal of Haematology - Wiley Online Library How I manage patients with follicular lymphoma - Casulo - 2019 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/9074358b-bc40-44c8-81e3-051706bcfedc/bjh16011-fig-0001-m.jpg)
How I manage patients with follicular lymphoma - Casulo - 2019 - British Journal of Haematology - Wiley Online Library
![Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology](https://www.thelancet.com/cms/attachment/c880e7d6-3884-4edd-a1bc-b882d7c24b3c/gr2_lrg.jpg)
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology
![M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/63eb1e27-7427-4152-ab57-27b36074b3fc/bjh.v188.2.cover.jpg?trick=1671240612207)
M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library
![Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/1d999e19-e581-453a-a14a-6322f3d076dc/gr1.jpg)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology
![Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels | Nature Cell Biology Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels | Nature Cell Biology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41556-020-0532-x/MediaObjects/41556_2020_532_Fig1_HTML.png)